RITUXIMAB TREATMENT OF PATIENTS WITH SEVERE, CORTICOSTEROID-RESISTANT THYROID-ASSOCIATED OPHTHALMOPATHY

摘要

Research Objective To report the effectiveness of anti-CD20 [rituximab (RTX); Rituxan; Genentech, Inc, South San Francisco, CA] therapy in patients with severe, corticosteroid (CS)-resistant thyroid-associated ophthalmo-pathy (TAO). Study Design Retrospective, interventional case series. Location University of California at Los Angeles, Los Angeles, CA. Funding Source The National Institutes of Health, Bethes-da, MD; Research to Prevent Blindness, Inc, New York, NY; Research to Prevent Blindness Career Development; and the Bell Charitable Foundation.